Teva Pharmaceutical Industries Ltd Adr (TEVA)

11:12 AM

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz

11:12 AM

Feb 26, 2026

Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz

Feb 26, 2026

Feb 25, 2026

Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz

Feb 25, 2026

Feb 23, 2026

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Benzinga

Feb 23, 2026

Feb 22, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm

Feb 22, 2026

Feb 20, 2026

Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz

Feb 20, 2026

Feb 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults - Sahm

Feb 20, 2026

Feb 19, 2026

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm

Feb 19, 2026

Feb 18, 2026

Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz

Feb 18, 2026

Feb 18, 2026

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Feb 18, 2026

Feb 18, 2026

Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus - Sahm

Feb 18, 2026

Feb 17, 2026

Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz

Feb 17, 2026

Feb 12, 2026

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm

Feb 12, 2026

Feb 10, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media

Feb 10, 2026

Feb 10, 2026

Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz

Feb 10, 2026

Feb 10, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm

Feb 10, 2026

Feb 09, 2026

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm

Feb 09, 2026

Feb 04, 2026

Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz

Feb 04, 2026

Feb 04, 2026

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm

Feb 04, 2026

Feb 04, 2026

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz

Feb 04, 2026

Feb 03, 2026

Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm

Feb 03, 2026

Feb 03, 2026

FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Feb 03, 2026

Feb 03, 2026

Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com

Feb 03, 2026

Feb 02, 2026

Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm

Feb 02, 2026

Feb 01, 2026

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm

Feb 01, 2026

Jan 31, 2026

Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz

Jan 31, 2026

Jan 31, 2026

Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz

Jan 31, 2026

Jan 30, 2026

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm

Jan 30, 2026

Jan 30, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World

Jan 30, 2026

Jan 29, 2026

Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm

Jan 29, 2026

Jan 29, 2026

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz

Jan 29, 2026

Jan 29, 2026

What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz

Jan 29, 2026

Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria

Jan 29, 2026

Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com

Jan 29, 2026

Jan 28, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm

Jan 28, 2026

Jan 28, 2026

Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com

Jan 28, 2026

Jan 28, 2026

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm

Jan 28, 2026

Jan 28, 2026

Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com

Jan 28, 2026

Jan 23, 2026

Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm

Jan 23, 2026

Jan 21, 2026

The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS

Jan 21, 2026

Jan 19, 2026

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz

Jan 19, 2026

Jan 19, 2026

Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.

Jan 19, 2026

Jan 18, 2026

This pharma stock “is beating everything”, investor says - Cantech Letter

Jan 18, 2026

Jan 16, 2026

How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story - Sahm

Jan 16, 2026

Jan 15, 2026

Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm

Jan 15, 2026